Incorporated in 2009, CanSinoBIO (SSE: 688185, HKEX: 06185) commits to providing high-quality, innovative, and affordable vaccines for global public health security. It possesses five integrated platform technologies upon which the company has established a rich portfolio of a pipeline products preventing more than 10 diseases, including the Aisa's first vaccine for Ebola virus disease Ad5-EBOV, the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Convidecia® approved in over 10 countries and granted EUL by the WHO, the Group A and Group C Meningococcal Conjugate Vaccine (CRM197) Menphecia® and the Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) Menhycia® approved by NMPA in China. The world's first inhaled COVID-19 vaccine Convidecia Air® has been approved as a booster dose in China, Morocco, and Indonesia. Additional information can be found online at www.cansinotech.com.
Company Details
- Employees
- 137
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.cansinotech.com
- Keywords
- Hengrui Pharma.
Cansino Biologics Inc.康希诺生物 Questions
Cansino Biologics Inc.康希诺生物's website is http://www.cansinotech.com
Cansino Biologics Inc.康希诺生物's LinkedIn profile is https://www.linkedin.com/company/%E5%BA%B7%E5%B8%8C%E8%AF%BA%E7%94%9F%E7%89%A9
Cansino Biologics Inc.康希诺生物 has
137 employees.
View email and phone details for 137
employees at Cansino Biologics Inc.康希诺生物.
Cansino Biologics Inc.康希诺生物's industry is
Biotechnology Research
Cansino Biologics Inc.康希诺生物's top competitors are
Amoéba,
Biontech Se,
Innovent Biologics,
Wuxi Biologics,
Porda Havas,
Sinovac Biotech Ltd.,
Astrazeneca,
Hengrui Pharma,
Tianjin Cansino Biotechnology Inc.,
Pfizer.
Cansino Biologics Inc.康希诺生物's categories are Biotechnology Research
Cansino Biologics Inc.康希诺生物's founding year is 2009
